MGTX NASDAQ
MeiraGTx Holdings plc
1W: -1.1%
1M: -23.3%
3M: -22.3%
YTD: +38.2%
1Y: +30.5%
3Y: +114.5%
5Y: -19.3%
$10.79
+0.13 (+1.22%)
Weekly Expected Move ±5.3%
$10
$10
$11
$11
$12
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
19 relationships19
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2022-11-10
Earliest Filing
2026-01-02
Latest Filing
partner: 13
investor: 5
acquirer: 1
Counterparties (Filed by MGTX)
19 relationshipsCompanies named in MGTX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Perceptive Life Sciences Master Fund, Ltd. | — | investor | Sold 2,300,000 ordinary shares to the Company for $18,193,000 in a share repurchase transaction. | 2026-01-02 | View |
| Perceptive Advisors LLC | — | investor | Affiliate of Perceptive Life Sciences Master Fund, Ltd. and parent of Perceptive Credit Holdings III, LP. | 2026-01-02 | View |
| Perceptive Credit Holdings III, LP | — | investor | Affiliate of Perceptive Life Sciences Master Fund, Ltd. that holds a $75 million note issued by the Company. | 2026-01-02 | View |
| Eli Lilly and Company | LLY | partner | Strategic collaboration and license agreement for genetic medicines in ophthalmology | 2025-11-10 | View |
| ARE-East River Science Park, LLC | — | partner | Entered into a Lease Agreement for laboratory and office facilities. | 2025-04-04 | View |
| ImClone Systems, LLC | — | partner | Counterparty to a Sublease agreement that was terminated. | 2025-04-04 | View |
| Hologen Limited | — | partner | Strategic collaborator entering into framework agreements for AI technology licensing, funding, and minority equity inve | 2025-03-13 | View |
| Hologen Neuro AI Limited | — | partner | Affiliate of Hologen Limited entering into collaboration and license agreements for clinical programs and delivery devic | 2025-03-13 | View |
| Hologen Neuro UK Limited | — | partner | Affiliate of Hologen Limited entering into collaboration and license agreements and receiving equity in Hologen Neuro. | 2025-03-13 | View |
| Hologen Guernsey | — | partner | Entity receiving Class B shares in Hologen Neuro in exchange for upfront payment and capital commitment. | 2025-03-13 | View |
| MeiraGTx Manufacturing Limited | — | partner | Wholly-owned subsidiary of MeiraGTx Holdings plc acquiring minority interest from Hologen Limited in its manufacturing b | 2025-03-13 | View |
| MeiraGTx Limited | — | partner | Wholly-owned subsidiary of MeiraGTx Holdings plc governing the board of MeiraGTx Manufacturing Limited. | 2025-03-13 | View |
| MeiraGTx Neuro UK Limited | — | partner | Wholly-owned subsidiary of MeiraGTx Holdings plc entering into collaboration agreements and receiving equity in Hologen | 2025-03-13 | View |
| MeiraGTx Neuro I, LLC | — | partner | Wholly-owned subsidiary of MeiraGTx Holdings plc receiving upfront payment under the Collaboration Agreement. | 2025-03-13 | View |
| Janssen Pharmaceuticals, Inc. | — | acquirer | Purchased the RPGR gene therapy product assets and license from MeiraGTx Holdings plc. | 2023-12-21 | View |
| Johnson & Johnson Innovation – JJDC, Inc. | JNJ | investor | Investment arm of Johnson & Johnson that owns more than 10% of MeiraGTx Holdings plc. | 2023-12-21 | View |
| Johnson and Johnson Innovation – JJDC, Inc. | — | investor | Private placement investor purchasing 3,742,514 ordinary shares for approximately $25.0 million | 2022-11-10 | View |
| Johnson & Johnson | JNJ | partner | Parent company of the Investor and party to a prior Collaboration, Option and License Agreement | 2022-11-10 | View |
| Janssen Pharmaceuticals, Inc. | — | partner | Counterparty to a Collaboration, Option and License Agreement dated January 30, 2019 | 2022-11-10 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-23 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-07-07 | Material Agreement; Termination of Agreement; Financial Obligation; Unregistered Equity Sales; Regul | Agreement | View |
| 2026-06-15 | Shareholder Vote | View | |
| 2026-05-14 | Earnings Release; Exhibits | View | |
| 2026-04-24 | Material Agreement; Exhibits | Agreement | View |
| 2026-04-16 | Regulation FD; Other Events; Exhibits | View | |
| 2026-04-16 | Material Agreement; Termination of Agreement; Acquisition/Disposition; Regulation FD; Other Events; | Agreement Acquisition | View |
| 2026-04-16 | Material Agreement; Exhibits | Agreement | View |
| 2026-03-26 | Material Agreement; Earnings Release; Financial Obligation; Exhibits | Agreement | View |
| 2026-01-02 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-11-10 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2025-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-26 | Regulation FD Disclosure | View | |
| 2025-06-17 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-05-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-05-09 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-04-04 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement | Agreement | View |
| 2025-03-13 | Entry into Material Definitive Agreement; Results of Operations and Financial Condition; Regulation | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR